Key Insights

Highlights

Treatment Research

4 treatments under study, led by Lebrikizumab

Research Leaders

7 sponsors active, led by Sanofi

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 2 (3)

Trial Status

Recruiting2
Not Yet Recruiting2

Clinical Trials (4)

Showing 4 of 4 trials
NCT07883213Phase 2Not Yet RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.

NCT07236099Phase 2RecruitingPrimary

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

NCT07620561Phase 2Not Yet RecruitingPrimary

Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

NCT07276425RecruitingPrimary

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

Showing all 4 trials

Research Network

Common Treatments

  • Lebrikizumab1
  • Icp3221
  • Dupilumab1
  • Ak1391

Active Sponsors

  • Sanofi1
  • University of Maryland, Baltimore1
  • Eli Lilly and Company1
  • UMC Utrecht1
  • Akeso1

Top Investigators

Related Conditions

  • Prurigo Nodularis1

Activity Timeline